Abstract
Brain function is the dynamic output of coordinated excitatory and inhibitory (E-I) activity. E-I alterations, arising from differences in excitatory glutamate and inhibitory GABA pathways, are implicated in the development and heterogeneity of multiple neurodevelopmental conditions, such as autism; and are consequently targets for pharmacological support options. Yet, E-I measures of neurotransmitter levels or receptors in the living human brain (such as Magnetic Resonance Spectroscopy or Positron Emission Tomography) are expensive and/or invasive and do not capture dynamics. The determine if a candidate metric captures a neurosignalling system, the system must be challenged and changes observed objectively. This is basis of animal study designs. The aperiodic 1/f exponent of the EEG power spectrum is sensitive to E-I perturbations in animals but, more work is needed to translate to humans. Therefore, we tested the hypotheses that i) the aperiodic 1/f exponent of resting-state EEG in humans changes following a pharmacological E-I challenge with arbaclofen, a GABAB receptor agonist; and ii) dynamic responsivity to GABAergic challenge is different in a neurodevelopmental condition associated with E-I differences, namely autism. As predicted, in both groups the aperiodic 1/f exponent significantly increased following a high (30mg) dose of arbaclofen. However, an aperiodic exponent increase was also elicited at a lower (15mg) dose of arbaclofen in autistic but not non-autistic individuals. Hence, in humans, the aperiodic 1/f exponent captures E-I dynamics and autistic brains are dynamically different compared to non-autistic brains. We suggest that our results can be explained by homeostatic differences E-I regulation between groups.
Competing Interest Statement
Prof. Murphy has received consultancy fees from F. Hoffmann La Roche and Servier. Prof McAlonan has received consultancy fees from Greenwich Biosciences and funding for an Investigator Initiated study from Compass Pathways Ltd. Prof McAlonan and Prof Murphy are supported by the Sackler Institute for Translational Neurodevelopment, the MRC Centre for Neurodevelopmental Disorders and the NIHR-Maudsley Biomedical Research Center. P. Garces is an employee of F. Hoffmann La Roche Ltd. There are no other declarations.
Clinical Trial
NCT03594552
Funding Statement
This project was funded by an Independent Investigator Award (G.M.M.) from the Brain and Behaviour Research Foundation and by Clinical Research Associates, L.L.C. (CRA), an affiliate of the Simons Foundation. Support is also acknowledged from Autistica and the Sackler Institute for Translational Neurodevelopment at King's College London and EU-AIMS (European Autism Interventions)/ AIMS-2-TRIALS, an Innovative Medicines Initiative Joint Undertaking under Grant Agreement No. 777394. In addition, this paper represents independent research part funded by the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre (BRC) at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval was granted by Kings College Research Ethics Committee (RESCM-17/18-4081).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
